• Explore /
  • Poster
  • / A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible muscle invasive bladder cancer (RAD VACCINE MIBC).

A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible muscle invasive bladder cancer (RAD VACCINE MIBC).

Abstract Poster

Authors

null

Raj Satkunasivam

Department of Urology and Center for Outcomes Research, Houston Methodist Hospital, Houston, TX

Raj Satkunasivam , Kelvin Lim , Bin S. Teh , Nestor F. Esnaola , Jeremy Slawin , Jun Zhang , Brian Miles , Michael Austin Brooks , Maryam Anis , Taliah Muhammad , Andrew M. Farach , Shu-Hsia Chen , Eleni Efstathiou , Guru P. Sonpavde

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT05241340

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS4611)

DOI

10.1200/JCO.2022.40.16_suppl.TPS4611

Abstract #

TPS4611

Poster Bd #

95b

Abstract Disclosures

Similar Posters

First Author: Deepak Kilari

First Author: Andrea Necchi

First Author: Guru P. Sonpavde

First Author: Deepak Kilari